Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease-Reference-Cited by-同舟云学术

Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease

Published:2004-04 Issue:9416 Volume:363 Page:1179-1183
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Van Camp Guy,Flamez Anja,Cosyns Bernard,Weytjens Caroline,Muyldermans Luc,Van Zandijcke Michel,De Sutter Johan,Santens Patrick,Decoodt Pierre,Moerman Christian,Schoors Danny

Publisher

Elsevier BV

Subject

General Medicine

Reference18 articles.

1. Pericardial, retroperitoneal, and pleural fibrosis induced by pergolide;Shaunak;J Neurol Neurosurg Psychiatry,1999

2. Retroperitoneal fibrosis in a patient with Parkinson's disease treated with pergolide;Jimenez-Jimenez;Clin Neuropharmacol,1995

3. Pergolide-induced retroperitoneal fibrosis;Mondal;Int J Clin Pract,2000

4. Pleuropulmonary disease due to pergolide use for restless legs syndrome;Danoff;Chest,2001

5. Valvular heart disease in patients taking pergolide;Pritchett;Mayo Clin Proc,2002

Cited by 285 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Senolytic and senomorphic secondary metabolites as therapeutic agents in Drosophila melanogaster models of Parkinson’s disease;Frontiers in Neurology;2023-09-28

2. Evaluation of pulmonary side effects in prolactinoma patients treated with cabergoline;Endokrynologia Polska;2023-07-18

3. The complex molecular pharmacology of the dopamine D2 receptor: Implications for pramipexole, ropinirole, and rotigotine;Pharmacology & Therapeutics;2023-05

4. Approach to the Patient With Prolactinoma;The Journal of Clinical Endocrinology & Metabolism;2023-03-28

5. Parkinson's disease and cardiovascular involvement: Edifying insights (Review);Biomedical Reports;2023-02-14